论文部分内容阅读
目的探讨复方牛胎肝提取物(安珐特)在治疗原发性肝癌行选择性肝动脉灌注化疗栓塞(TACE)术后肝纤维化的临床疗效。方法收集2012年1月至2014年1月原发性肝癌患者40例,均于TACE术后行MRI弥散加权成像(DWI)、肝纤维化指标[透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)及IV型胶原(Ⅳ-C)]诊断为肝纤维化,将患者随机分为两组:对照组20例,TACE术后即给予甘草酸二铵胶囊常规口服;实验组20例,在常规给予甘草酸二铵胶囊口服基础上,给予安珐特口服。于治疗6个月后复查DWI、肝功能及肝纤维化指标,分析治疗前后DWI的表观弥散系数(ADC)值,HA、LN、PCⅢ、Ⅳ-C及肝功能的变化。结果实验组患者治疗6个月后较治疗前肝纤维化指标(HA、LN、PCⅢ、Ⅳ-C)明显降低(P<0.05,P<0.01),ADC值明显升高(P<0.05),肝功能(ALT、AST、TBIL、ALB)明显改善(P均<0.05);而对照组患者治疗后的肝纤维化指标、ADC值及肝功能虽有好转,但差异无统计学意义(P均>0.05)。结论安珐特可以抗原发性肝癌TACE术后肝纤维化,有助于TACE术后肝功能的恢复。
Objective To investigate the clinical efficacy of compound fetal bovine liver extract (Ampul) in the treatment of primary liver cancer with selective hepatic arterial infusion chemoembolization (TACE). Methods Forty patients with primary liver cancer between January 2012 and January 2014 were recruited. All patients underwent MRI diffusion weighted imaging (DWI) and hepatic fibrosis indexes [hyaluronic acid (HA), laminin (LN) after TACE. ), type III procollagen (PCIII) and type IV collagen (IV-C) were diagnosed as hepatic fibrosis. The patients were randomly divided into two groups: the control group (20 cases). Diamonium glycyrrhizinate capsules were given orally after TACE. In the experimental group, 20 patients were given orally to the oral administration of diammonium glycyrrhizinate capsules orally. After 6 months of treatment, DWI, liver function and hepatic fibrosis were reviewed. The apparent diffusion coefficient (ADC) values, HA, LN, PCIII, IV-C, and liver function were analyzed before and after treatment. Results In the experimental group, the liver fibrosis indexes (HA, LN, PCIII, IV-C) were significantly lower than those before treatment (P<0.05, P<0.01), and the ADC value was significantly increased (P<0.05). Liver function (ALT, AST, TBIL, ALB) was significantly improved (P<0.05), while liver fibrosis indexes, ADC values, and liver function were improved in the control group, but the difference was not statistically significant (P average >0.05). [Conclusion] Ancide can hepatic fibrosis after TACE for hepatocellular carcinoma, which is helpful for the recovery of hepatic function after TACE.